The FDA has approved a new inhaler to treat narrowing of the lung airways associated with COPD.
The Tudorza Pressair (aclidinium bromide) inhaler has been approved by the FDA to treat narrowing of the lung airways associated with COPD in people 18 and older.
The inhaler, to be used twice daily, relaxes muscles around the lung's large airways, improving breathing. It is not meant to be used as a rescue inhaler during sudden asthma attacks, the agency said.
Common side effects observed during clinical testing included headache, nasal inflammation, and cough.
The inhaler is distributed by St. Louis-based Forest Pharmaceuticals, a subsidiary of Forest Laboratories.
—Brought to you by HealthDay News